Size: | Price | Quantity | |
---|---|---|---|
5 mg | $45.00 | ||
25 mg | $150.00 |
Pexidartinib (1029044-16-3) is a potent and selective dual inhibitor of CSF1R (IC50 = 20nM) and c-KIT (IC50 = 10nM).1 Inhibition of CSF1R with Pexidartinib resulted in a reprogrammed immune microenvironment that fosters antitumor immunity in a CD8+ T-cell-dependent manner in a breast cancer model.1 CSF1R recruits tumor-infiltrating myeloid cell that suppress tumor immunity – Pexidartinib increased the efficacy of adoptive cell immunotherapy (ACT) in a mouse melanoma model by inhibiting the intratumoral accumulation of immunosuppressive macrophages.2,3 It has also been shown to increase the efficacy of anti-PD-14,5 and DC immunotherapy 6.
References/Citations:
1) DeNardo et al. (2011) Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy; Cancer Discov. 1 54
2) Mok et al. (2014) Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy; Cancer Res.74 15
3)Sluijter et al. (2014) Inhibition of CSF-1R supports T-cell mediated melanoma therapy; PLoS One 9 e104230
4) Peranzoni et al. (2018) Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment; Proc. Natl. Acad. Sci. USA 115 E4041
5) Shi et al. (2019) Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy; Mol. Ther. 27 244
6) Dammeijer et al. (2017) Depletion pf Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy; Cancer Immunol. Res. 5 535
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Pexidartinib (1029044-16-3) is a potent and selective dual inhibitor of CSF1R (IC50 = 20nM) and c-KIT (IC50 = 10nM).1 Inhibition of CSF1R with Pexidartinib resulted in a reprogrammed immune microenvironment that fosters antitumor immunity in a CD8+ T-cell-dependent manner in a breast cancer model.1 CSF1R recruits tumor-infiltrating myeloid cell that suppress tumor immunity – Pexidartinib increased the efficacy of adoptive cell immunotherapy (ACT) in a mouse melanoma model by inhibiting the intratumoral accumulation of immunosuppressive macrophages.2,3 It has also been shown to increase the efficacy of anti-PD-14,5 and DC immunotherapy 6.
References/Citations:
1) DeNardo et al. (2011) Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy; Cancer Discov. 1 54
2) Mok et al. (2014) Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy; Cancer Res.74 15
3)Sluijter et al. (2014) Inhibition of CSF-1R supports T-cell mediated melanoma therapy; PLoS One 9 e104230
4) Peranzoni et al. (2018) Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment; Proc. Natl. Acad. Sci. USA 115 E4041
5) Shi et al. (2019) Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy; Mol. Ther. 27 244
6) Dammeijer et al. (2017) Depletion pf Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy; Cancer Immunol. Res. 5 535
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.